{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:10:20Z","timestamp":1778944220767,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008376","name":"HUS Helsinki University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004212","name":"Paivikki and Sakari Sohlberg Fundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Cancer Foundation Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9lius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008723","name":"Finnish Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003756","name":"Biomedicum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003756","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clgc.2026.102563","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T16:37:31Z","timestamp":1776443851000},"page":"102563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["International Survey of Thromboprophylaxis Practices During Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6597-818X","authenticated-orcid":false,"given":"Alex L.E.","family":"Halme","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matias","family":"Posa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4028-5220","authenticated-orcid":false,"given":"Jani","family":"Ruotsalainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanna","family":"Hallamies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9369-8628","authenticated-orcid":false,"given":"Andreas","family":"Carus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigurdur","family":"Gudjonsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1932-500X","authenticated-orcid":false,"given":"Heikki","family":"Junkkari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riikka","family":"J\u00e4rvinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niko K.","family":"Nordlund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Tornberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9023-3259","authenticated-orcid":false,"given":"Anders","family":"Ull\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter L.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsi-Maija","family":"Kaukonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.F.","family":"Catto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed A.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1389-8214","authenticated-orcid":false,"given":"Kari A.O.","family":"Tikkinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clgc.2026.102563_bib0001","doi-asserted-by":"crossref","first-page":"381.e1","DOI":"10.1016\/j.urolonc.2022.04.006","article-title":"Venous thromboembolism risk in patients receiving neoadjuvant chemotherapy for bladder cancer","volume":"40","author":"Garas","year":"2022","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102563_bib0002","doi-asserted-by":"crossref","first-page":"320","DOI":"10.23736\/S2724-6051.24.05699-4","article-title":"The impact of venous thromboembolism before open or minimally-invasive radical cystectomy in the USA: insurance claims data on perioperative outcomes and healthcare costs","volume":"76","author":"Del Giudice","year":"2024","journal-title":"Minerva Urol Nephrol"},{"key":"10.1016\/j.clgc.2026.102563_bib0003","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-066785","article-title":"Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials","volume":"376","author":"Marcucci","year":"2022","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.clgc.2026.102563_bib0004","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"AVERT: apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clgc.2026.102563_bib0005","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102563_bib0011","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0302-2838(26)01799-9","article-title":"P0944 Thrombosis and major bleeding in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"89","author":"Halme","year":"2026","journal-title":"Eur Urol"},{"issue":"18","key":"10.1016\/j.clgc.2026.102563_bib0006","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1161\/CIRCULATIONAHA.110.015008","article-title":"Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry","volume":"124","author":"Pepke-Zaba","year":"2011","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.clgc.2026.102563_bib0007","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102563_bib0008","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102563_bib0009","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5489\/cuaj.7865","article-title":"A survey of physician perception and practices regarding pharmacological thromboprophylaxis during chemotherapy for bladder cancer","volume":"16","author":"Amenyogbe","year":"2022","journal-title":"Can Urol Assoc J"},{"issue":"7","key":"10.1016\/j.clgc.2026.102563_bib0010","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0676","article-title":"Fundamental research in oncology and thrombosis 2 (FRONTLINE 2): a follow-up survey","volume":"25","author":"Kakkar","year":"2020","journal-title":"The Oncologist"},{"issue":"19","key":"10.1016\/j.clgc.2026.102563_bib0012","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.clgc.2026.102563_bib0013","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"issue":"7_suppl","key":"10.1016\/j.clgc.2026.102563_bib0014","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA630","article-title":"Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: randomized, open-label, phase 3 KEYNOTE-B15 study","volume":"44","author":"Galsky","year":"2026","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102563_bib0015","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102563_bib0016","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251357519","article-title":"Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States","volume":"17","author":"You","year":"2025","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102563_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-103709","article-title":"Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom","volume":"15","author":"Wu","year":"2025","journal-title":"BMJ Open"},{"issue":"17","key":"10.1016\/j.clgc.2026.102563_bib0018","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clgc.2026.102563_bib0019","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.clgc.2026.102563_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(24)00281-3","article-title":"Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants","volume":"11","author":"Ageno","year":"2024","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102563_bib0021","article-title":"Thromboprophylaxis practice patterns and beliefs among physicians treating patients with abdominopelvic cancers at a Canadian centre","volume":"63","author":"McAlpine","year":"2020","journal-title":"Can J Surg J Can Chir"},{"issue":"7","key":"10.1016\/j.clgc.2026.102563_bib0022","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/jth.14149","article-title":"Venous thromboembolism in cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis","volume":"16","author":"Di Nisio","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.clgc.2026.102563_bib0023","article-title":"Venous thromboembolism rate in patients with bladder cancer according to the type of treatment: a systematic review","volume":"14","author":"Abdullah","year":"2022","journal-title":"Cureus"},{"issue":"9","key":"10.1016\/j.clgc.2026.102563_bib0024","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.urolonc.2016.05.009","article-title":"High rates of venous thromboembolic events in patients undergoing systemic therapy for urothelial carcinoma: a systematic review and meta-analysis","volume":"34","author":"Gopalakrishna","year":"2016","journal-title":"Urol Oncol"},{"issue":"17","key":"10.1016\/j.clgc.2026.102563_bib0025","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.2217\/imt-2022-0039","article-title":"Neoadjuvant immunochemotherapy in the treatment of nonmetastatic muscle-invasive bladder cancer: a systematic review","volume":"14","author":"Sarkis","year":"2022","journal-title":"Immunotherapy"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:30:04Z","timestamp":1778941804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1558767326000637"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102563","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"International Survey of Thromboprophylaxis Practices During Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102563"}}